Abbott Slashes 700 Jobs From Its Medical Devices and Diagnostics Unit
.jpg)
Chicago-based Abbott Laboratories today announced that it would lay off 700 employees from its medical devices and diagnostics division as part of an ongoing restructuring effort.
Most of the layoffs will take place in the Chicago area and affect employees that manufacture the company’s cardiovascular stents and diagnostic tests. According to a company spokesperson approximately 500 persons who work in stent manufacturing and 200 who work in diagnostics will lose their jobs.
The restructuring of Abbott’s manufacturing operations began several years ago and about this time last year the company layed off about 1,900 employees in Lake County, Illinois.
In October, Abbott surprised investors and analysts with the announcement that it would spin off its branded drug business, including Humira (psoriasis and rheumatoid arthritis) it’s largest selling branded pharmaceutical product. Company executives argued that the split would allow stakeholders and investors to separately and more accurately value Abbott’s other less risky businesses which include nutritional (baby) formula, generic drugs and medical devices and diagnostics.
Despite signs of economic recovery, it appears that layoffs are still occurring at a pretty good clip at many pharma and biotech companies. It now appears that medical devices and diagnostic company employees, who were once immune to downsizing and reorganization, are now fair game.
Until next time...
Good Luck and Good Job Hunting!!!!
Takeda Pharmaceutical Company, Japan’s largest pharmaceutical company, yesterday announced its intention to purchase the Swiss drug maker Nycomed for 8 to 10 billion euros ($11.4-14 billion). While the deal is not certain to close, it signals Takeda’s intention to purchase its way into the US and European markets.
The world’s largest generic pharmaceutical company Teva Pharmaceuticals Industries LTD today 
Big pharma continues to lament the increased scrutiny being imposed on it by the US Food and Drug Administration (FDA). Like it or not, the agency’s directive is to insure that the drugs that it approves are safe and effective for the American public. And, for the most part, the agency does its job and frequently catches companies that attempt to break the rules..jpg)
There is no question that Twitter is the new social media tool of the moment. And, it should come as no surprise that scientists and other bioprofessionals have been slow to jump on the Twitter bandwagon. While the jury is still out on Twitter’s effectiveness as a research tool, there is a growing body of evident that suggests that it can be a valuable tool when conducting a job search. .jpg)
Swiss pharmaceutical giant Novartis .png)
A positive workplace environment can make or break a company. Companies with low employee morale often suffer from cultures of blame—pointing a finger at a team member (other than you) when things go awry —and not giving credit to deserving employees when credit may be due. 
After seven months of public bickering over an appropriate sale price, the NY Time 
Five years ago Amgen was the world’s largest biotechnology and was, by many accounts, the darling of Wall Street. But, today, there is little mention of the once formidable biotechnology company that many startups attempted to emulate. Like other companies, Amgen ran into pipeline problems, medical issues with existing blockbuster drugs (remember the whole hematocrit brouhaha over Epogen and Aranesp its flagship anemia products), lower drug sales and ultimately the perception that the company had lost its innovative edge. However, it now appears that Amgen is making something of a comeback and may have been quietly preparing itself for its “rebirth” over the past few years..jpg)
The New York Times
Johnson & Johnson is arguably one of the world leaders in bringing social media to the pharmaceutical industry. Marc Monseau and his dedicated team oversee a network of blogs, video channels and Twitter feeds while some of J&J’s brand companies even sponsor patient advocacy communities like ADHD Moms and ADHD Allies. However, the company’s recent handling of manufacturing problems and recall of Tylenol and other pediatric medicines seemingly flies in the face of openness and transparency; two of the underlying tenets and guiding principles of social media.
Bristol-Myers Squibb (BMS) announced Tuesday that its board authorized the 
A common lament from that I frequently hear from graduate students and postdoctoral scientists at career development meetings is the need for "prior industry experience" to qualify and be considered for an industrial science job. Invariably, someone asks: “How in the world am I supposed to get industrial experience if nobody is willing to hire me as an industrial scientist?” Prior to the financial meltdown, I frequently advised PhD-trained scientists seeking industrial jobs to consider positions in smaller, local biotechnology companies.
As many of you may recall, in 2001, Sam Waksal, founder and former CEO of the biotechnology company .jpg)
It is getting difficult to keep track of the job cuts that are happening almost daily at Pfizer. A quick perusal of the job cuts to date indicate that the company has eliminated about 1200 jobs in the past week;
In a previous post I .jpg)
Word on the street suggests that Roche has severed its relationship with the Pharmaceutical Manufacturers of America (PhRMA) the trade group that represents and lobbies on behalf of the pharmaceutical industry. The recent purchase of Genentech must have convinced the venerable 100 year old pharmaceutical company that proteins not small molecule drugs are the key to its future.
Did you know that the top ten pharmaceutical companies in the world spent close to $50 billion dollars last year on R&D? That sum could be used to purchase the entire US biotechnology industry except for the five largest companies—Genentech, Amgen, Gilead Genzyme and Celgene. Further, pharma’s R&D budget is about 4 times the R&D budget of all of the US biotechnology companies combined. According to a.jpg)
In a .jpg)
Do you ever wonder what the person who you share an office with is making? Or, have you ever wondered what other people think about the CEO of your company? Or, should I consider working at that company? The answers to these questions and more can now be found at a 4-month old website called 
It looks as though Enzon Pharmaceuticals, the first company to successfully commercialize protein PEGylation, finally buckled under the pressure exerted by Carl Icahn, one of its major shareholders. As I mentioned in a 